益佰制药(600594) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥572,646,100.11, representing a decrease of 16.26% compared to the same period last year[7]. - The net profit attributable to shareholders of the listed company was -¥68,454,808.45, a decline of 255.58% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥70,793,005.20, down 322.54% from the previous year[7]. - The basic and diluted earnings per share were both -¥0.086, reflecting a decrease of 253.57% compared to the same period last year[7]. - The total operating revenue for Q1 2024 was ¥572,646,100.11, a decrease of 16.2% compared to ¥683,797,926.88 in Q1 2023[41]. - The net profit attributable to the parent company's shareholders for Q1 2024 was CNY -68.45 million, a decrease from CNY 43.99 million in Q1 2023[47]. - The total comprehensive income for Q1 2024 was CNY -71.37 million, down from CNY 41.36 million in Q1 2023[47]. - The company reported a total profit of CNY -69.77 million for Q1 2024, compared to CNY 52.72 million in Q1 2023, marking a significant decline[45]. Cash Flow and Assets - The net cash flow from operating activities increased by 62.86%, amounting to ¥95,754,548.97, primarily due to an increase in sales collections[7][14]. - Current assets totaled ¥2,035,731,291.56 as of March 31, 2024, slightly down from ¥2,069,148,018.19 at the end of 2023[35]. - Cash and cash equivalents increased to ¥770,599,925.85 from ¥699,468,723.75, reflecting a growth of 10.4%[35]. - Total assets at the end of the reporting period were ¥4,705,798,361.89, down 1.56% from the end of the previous year[9]. - The ending balance of cash and cash equivalents was $766,811,919.96, up from $680,005,534.66 at the end of the previous period[52]. - The beginning balance of cash and cash equivalents was $695,680,717.86, compared to $585,355,390.28 in the previous year[52]. - Total cash and cash equivalents increased by $71,131,202.10, down from an increase of $94,650,144.38 in the prior period[52]. Shareholder Information - The company reported a significant shareholder, Dou Qiling, holding 185,457,636 shares, representing 23.42% of total shares, with 129,820,300 shares pledged[19]. - The top ten shareholders include notable entities such as Guangzhou Zhujiang Development Group and Guangzhou Zhujiang Industrial Group, holding 1.04% and 1.22% of shares respectively[19]. - The company’s top ten shareholders have not changed significantly in terms of their shareholding status during the reporting period[22]. - The company’s total shares held by the top ten unrestricted shareholders amount to 185,457,636 shares[19]. Regulatory and Operational Issues - The significant decline in net profit was mainly due to the suspension of the production of Aidi injection, leading to a substantial decrease in revenue[14]. - The company received an administrative penalty notice from the Guizhou Provincial Drug Administration, impacting the production of its product, Eidi Injection, which has been halted[24]. - The company received a warning letter from the Guizhou Securities Regulatory Bureau for failing to disclose the impact of its major product's production halt[29]. - The company’s major product, Eidi Injection, has an uncertain future regarding production due to regulatory issues, which may significantly affect its financial performance[24]. Share Repurchase Plan - The company plans to repurchase shares using its own funds, with a budget between RMB 20 million and RMB 40 million, at a maximum price of RMB 8.65 per share[30]. - The company has not yet implemented the share repurchase plan as of the reporting date[30]. Liabilities and Expenses - Total liabilities amounted to ¥1,575,815,591.27, a slight decrease from ¥1,578,998,904.30[40]. - Long-term borrowings decreased significantly to ¥248,424,504.44 from ¥387,224,504.44, a reduction of 35.9%[40]. - The company incurred financial expenses of CNY 8.07 million in Q1 2024, a significant increase from CNY 0.86 million in Q1 2023[45]. - Research and development expenses for Q1 2024 were CNY 22.80 million, slightly up from CNY 22.46 million in Q1 2023[45].